Haisco(SZ:002653) Zhi Tong Cai Jing·2025-09-03 07:58Core Viewpoint - The company, HaiSiKe (002653.SZ), has received approval from the National Medical Products Administration for clinical trials of its self-developed drug HSK47388, which is intended for the treatment of autoimmune diseases [1] Group 1: Drug Development - HSK47388 is an oral, potent, and highly selective drug developed by the company [1] - The drug has shown significant dose-dependent efficacy in preclinical studies using rat models of enteritis [1] - HSK47388 demonstrates good tolerability and a large safety window, indicating strong development potential [1] Group 2: Clinical Trial Approval - The approval allows HSK47388 to proceed with clinical trials for a new indication in the field of autoimmune diseases [1] - This development is expected to provide a new treatment option for patients suffering from autoimmune diseases [1]